Pediatric Praziquantel Consortium

From the Program Lead: Progress made over the last year

24 September 2021

The ADOPT Program: Paving the way for access & delivery

24 September 2021

A new formulation to fight Schistosomiasis


A pediatric formulation of Praziquantel has been developed for schistosomiasis.
Video credits: The GHIT Fund

Vision

Our vision is to reduce the global disease burden of schistosomiasis by addressing the medical need of infected preschool-age children including infants and toddlers.

Read more

Mission

Our mission is to develop, register and provide access to a suitable pediatric praziquantel formulation for treating schistosomiasis in preschool-age children.

Read more

Development & registration program

The consortium established a pediatric drug development program, divided into three major steps: preclinical development, clinical development and registration and access.

Read more

Access program

The Consortium is developing an Access strategy by exploring new procurement and business models and conducting implementation research to ensure the new pediatric treatment is available free of charge to the young patients in need.

Read more